Hannah Wyman, OTR/L in Lake Park, FL - Preventive Medicine

Hannah Wyman, OTR/L is a Preventive Medicine - Occupational Medicine physician based in Lake Park, Florida. Hannah Wyman is licensed to practice in Florida (license number OT18559) and her current practice location is 9182 Roan Ln, Lake Park, Florida. She can be reached at her office (for appointments etc.) via phone at (561) 246-2830.

NPI number for Hannah Wyman is 1740707165 and her current mailing address is 9182 Roan Ln, Lake Park, Florida. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1740707165.

Contact Information

	Hannah Wyman, OTR/L
	9182 Roan Ln, Lake Park, FL 33403-1030
	(561) 246-2830
	Not Available

Physician's Profile

Full Name	Hannah Wyman
Gender	Female
Speciality	Preventive Medicine - Occupational Medicine
Location	9182 Roan Ln, Lake Park, Florida
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1740707165
Provider Enumeration Date: 08/25/2017
Last Update Date: 07/21/2022

Medical Identifiers

Medical identifiers for Hannah Wyman such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1740707165	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
2083X0100X	Preventive Medicine - Occupational Medicine	OT18559 (Florida)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Hannah Wyman is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Hannah Wyman, OTR/L 9182 Roan Ln, Lake Park, FL 33403-1030 Ph: (561) 246-2830	Hannah Wyman, OTR/L 9182 Roan Ln, Lake Park, FL 33403-1030 Ph: (561) 246-2830

News Archive

Health Canada approves Genzyme's Lemtrada for adults with relapsing remitting multiple sclerosis

Genzyme, a Sanofi company, announced today that Health Canada has approved Lemtrada (alemtuzumab) for the management of adult patients with relapsing remitting multiple sclerosis, with active disease defined by clinical and imaging features, who have had an inadequate response to interferon beta or other disease-modifying therapies.

Researchers find no serious adverse effects of HPV vaccine in girls

Researchers at Karolinska Institutet in Sweden and their Danish colleagues have monitored HPV-vaccinated girls via patient data registries in order to examine the incidence of a wide range of diseases and thus determine if there are any serious adverse effects of the vaccine. Their results show no significant increase of the examined diseases in the vaccinated girls relative to their unvaccinated peers.

Discovery of neuropilin 2 deficiency may lead to new therapies for edema and lymphedema

Fluid accumulation and swelling (edema) may result from the malfunctioning of regulatory processes controlling vessel permeability in the body.

Discovery of possible preventative therapy for type 1 diabetes

Scientists believe they may have found a preventative therapy for type 1 diabetes, by making the body's killer immune cells tolerate the insulin-producing cells they would normally attack and destroy, prior to disease onset.

Hannah Wyman, OTR/L - Preventive Medicine in Lake Park, FL